Japanese Dengue Vaccine TAK-003 Approved for Use in Argentina
Argentine health authorities have officially approved the use of TAK-003, a dengue vaccine developed by the Japanese laboratory Takeda, for individuals aged 4 and over. This decision, announced by the National Administration of Medicines, Food and Medical Technology (ANMAT), marks a significant step in the fight against dengue in Argentina.
Vaccine Details and Approval
TAK-003, also known as Qdenga, is designed to be administered in two doses, three months apart. It is based on dengue virus 2, with DNA from the other three serotypes added to ensure protection against all four types of dengue. This innovative approach aims to provide comprehensive immunity against the disease.
The vaccine received its first approval in Indonesia in August 2022, followed by the European Union in December 2022, and most recently in Brazil. The approval in Argentina is a testament to the vaccine's efficacy and safety profile.
Dengue Situation in Argentina
The approval comes at a critical time, as Argentina faces a significant outbreak of dengue. Between July 31, 2022, and April 22, 2023, the country reported more than 71,700 dengue infections and 53 deaths. Notably, 65,195 of these cases had no travel history, indicating community transmission of the virus.
The districts most affected include the city of Buenos Aires and the provinces of Tucumán, Salta, Jujuy, Santa Fe, and Santiago del Estero, all reporting more than 100 dengue cases per 100,000 inhabitants.
Moving Forward
Following the approval, Takeda will establish protocols for the production and shipment of the vaccine to Argentina. This development is a beacon of hope for controlling the spread of dengue and reducing the disease's impact on public health in the region.
As dengue cases continue to rise, the introduction of TAK-003 offers a promising solution to combat this mosquito-borne disease, potentially saving lives and reducing the burden on healthcare systems.
